Match tier
Institution-verified
Presence
Formerly Arkansas
Last published
2025
Sources
Institutional record
Refreshed
2026-10-08
D
Daisy Alapat
Sourced from institutional research profiles (UAMS TRI or ARA).
Professor
Also affiliated: University of Arkansas Medical Center (2025); Arkansas Department of Agriculture (2022)
Formerly Arkansas Professor, University of Arkansas through 2026; now Professor, University of Arkansas for Medical Sciences.
3 h-index
8 pubs
74 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Daisy Alapat's research focuses on hematologic malignancies, particularly multiple myeloma and Castleman disease. Her work investigates the immune microenvironment's role in disease progression and precursor stages, utilizing single-cell and multi-omics approaches. Alapat has contributed to studies characterizing the heterogeneity of Castleman disease, including findings from the ACCELERATE registry, and has examined treatment consistency with idiopathic multicentric Castleman disease guidelines for improved outcomes. Her research also explores the clinical implications of minimal residual disease negativity in multiple myeloma and the impact of specific gene expression, such as NEK2, on T-cell immunity in this context. Alapat is also involved in long-term follow-up studies of multiple myeloma treatment regimens, such as Total Therapy IIIB. She has a significant publication record with key collaborators at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, Guido Tricot, Sharmilan Thanendrarajan, and John D. Shaughnessy.
Metrics
- h-index: 3
- Publications: 8
- Citations: 74
Positions
-
Professor publications 2020–2025University of Arkansas for Medical Sciences Institution web page
-
Professor 2022–2026University of Arkansas for Medical Sciences Medical Center Pathology ORCID
Selected Publications
-
POSTER: IBCL-492: Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses (2026)
-
IBCL-492: Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses (2026)
-
Testicular Plasmacytoma: A 25-Year Experience from a High-Volume Tertiary Center and Comparative Review of the Literature (2026)
-
Post‐transport macroscopic aggregates in a filtered bone marrow harvest bag (2026)
-
Illuminating Blurry Vision: Visualization of Corneal Protein Deposition With Immunofluorescence in Two Illustrative Case Reports (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Breast-implant associated unicentric castleman disease: a case report (2026)
-
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspective (2025)
-
Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab (2025)
-
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans (2025)
-
When less is more: the role of non-vitrectomized vitreous surgery in retinal diseases (2025)
-
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castleman disease. (2025)
-
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry (2025)
Collaboration Network
Top Collaborators
Frits van Rhee
Winthrop Rockefeller Foundation
56 shared publications
In database
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
Showing 5 of 56 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
43 shared publications
In database
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
Showing 5 of 43 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
41 shared publications
In database
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 41 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
38 shared publications
In database
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 38 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
28 shared publications
In database
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
Showing 5 of 28 shared publications
Samer Al Hadidi
Winthrop Rockefeller Foundation
18 shared publications
In database
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 18 shared publications
Clyde Bailey
Winthrop Rockefeller Foundation
17 shared publications
In database
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 17 shared publications
Gareth J. Morgan
NYU Langone Health (US)
16 shared publications
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias
Showing 5 of 16 shared publications
Joshua Epstein
University of Arkansas for Medical Sciences (US)
14 shared publications
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
Showing 5 of 14 shared publications
Faith E. Davies
NYU Langone Health (US)
14 shared publications
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
Showing 5 of 14 shared publications
Cody Ashby
University of Arkansas for Medical Sciences
14 shared publications
In database
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 14 shared publications
Adam Bagg
University of Pennsylvania (US)
14 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
Showing 5 of 14 shared publications
Mary Jo Lechowicz
Emory University (US)
14 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
Showing 5 of 14 shared publications
Gordan Srkalović
Sparrow Health System (US)
14 shared publications
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
Showing 5 of 14 shared publications
John D. Shaughnessy
Winthrop Rockefeller Foundation
13 shared publications
In database
- Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Showing 5 of 13 shared publications
Similar Researchers
Based on overlapping research topics
B Poudel
University of Arkansas – Fort Smith
Immune Response and Inflammation
Disease Mechanisms Research
Medical Case Studies
Manojna Konda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Disease Mechanisms Research
Medical Case Studies
Morgan Tripod
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Disease Mechanisms Research
Medical Case Studies
Yanping Izak Harville
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Disease Mechanisms Research
Medical Case Studies
B Moreno-Lujano
University of Arkansas – Fort Smith
Immune Response and Inflammation
Disease Mechanisms Research
Retrospective Studies
David E. Mery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Disease Mechanisms Research